Difference between revisions of "Nivolumab and relatlimab (Opdualag)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) |
m |
||
| Line 10: | Line 10: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*3/18/2022: Approved for adult and pediatric patients 12 years of age or older with unresectable or metastatic [[melanoma]]. ''(Based on RELATIVITY-047)'' | *3/18/2022: Approved for adult and pediatric patients 12 years of age or older with unresectable or metastatic [[melanoma]]. ''(Based on RELATIVITY-047)'' | ||
| − | + | ==History of changes in EMA indication== | |
| + | *9/15/2022: initial authorization | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' BMS-986016 | *'''Code name:''' BMS-986016 | ||
| Line 22: | Line 23: | ||
[[Category:Melanoma medications]] | [[Category:Melanoma medications]] | ||
[[Category:Combination drugs]] | [[Category:Combination drugs]] | ||
| + | [[Category:EMA approved in 2022]] | ||
[[Category:FDA approved in 2022]] | [[Category:FDA approved in 2022]] | ||
Revision as of 13:55, 31 December 2022
Mechanism of action
From the NCI Drug Dictionary (for relatlimab): A monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, relatlimab binds to LAG-3 on tumor infiltrating lymphocytes (TILs). This may activate antigen-specific T lymphocytes and enhance cytotoxic T cell-mediated tumor cell lysis, which leads to a reduction in tumor growth.
Toxicity management
Diseases for which it is used
History of changes in FDA indication
- 3/18/2022: Approved for adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. (Based on RELATIVITY-047)
History of changes in EMA indication
- 9/15/2022: initial authorization
Also known as
- Code name: BMS-986016
- Generic name: nivolumab and relatlimab-rmbw
- Brand name: Opdualag